Amplified in breast cancer 1 expression in breast cancer

M. A. Thorat, D. Turbin, A. Morimiya, S. Leung, Q. Zhang, M. H. Jeng, D. G. Huntsman, Harikrishna Nakshatri, Sunil Badve

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aims: The amplified in breast cancer 1 (AIB1), steroid receptor co-activator family member, acts as an oestrogen receptor (ER) co-activator. Acting with HER-2, it is thought to play a role in endocrine resistance by facilitating ER-growth factor crosstalk. The aim was to analyse AIB1 expression by immunohistochemistry and study its correlations with other prognostic variables in breast cancer and its effect on survival. Methods: A tissue microarray comprising tumours from 438 patients with 15.4 years' median follow-up was used. Interpretable AIB1 expression obtained in 395 patients was analysed along with other prognostic factors in breast cancer. Results: AIB1 expression scores ranged from 0 to 30; positive AIB1 expression (score > 14) was seen in 146/395 breast cancers; it correlated negatively with ER (P = 0.003) and progesterone receptor (PR) (P = 0.007), and positively with HER-2 (P = 0.005) and tumour grade (P = 0.014). It did not correlate with nodal status (P = 0.437). Among ER+ patients, AIB1 expression showed a trend towards loss of PR expression (29% versus 20%; P = 0.14). AIB1 did not predict survival on univariate or multivariate analysis. Conclusions: AIB1 expression correlates with HER-2 expression in breast cancer and shows a trend of association with loss of PR expression in ER+ tumours. Our study supports the postulated role of AIB1 in ER-growth factor interactions.

Original languageEnglish
Pages (from-to)634-641
Number of pages8
JournalHistopathology
Volume53
Issue number6
DOIs
StatePublished - Dec 2008

Fingerprint

Breast Neoplasms
Progesterone Receptors
Intercellular Signaling Peptides and Proteins
Neoplasms
Survival
Steroid Receptors
Estrogen Receptors
Multivariate Analysis
Immunohistochemistry

Keywords

  • Amplified in breast cancer 1
  • Breast cancer
  • Human epidermal growth factor receptor 2
  • Oestrogen receptor
  • Prognosis
  • Steroid receptor co-activator 3

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

Thorat, M. A., Turbin, D., Morimiya, A., Leung, S., Zhang, Q., Jeng, M. H., ... Badve, S. (2008). Amplified in breast cancer 1 expression in breast cancer. Histopathology, 53(6), 634-641. https://doi.org/10.1111/j.1365-2559.2008.03155.x

Amplified in breast cancer 1 expression in breast cancer. / Thorat, M. A.; Turbin, D.; Morimiya, A.; Leung, S.; Zhang, Q.; Jeng, M. H.; Huntsman, D. G.; Nakshatri, Harikrishna; Badve, Sunil.

In: Histopathology, Vol. 53, No. 6, 12.2008, p. 634-641.

Research output: Contribution to journalArticle

Thorat, MA, Turbin, D, Morimiya, A, Leung, S, Zhang, Q, Jeng, MH, Huntsman, DG, Nakshatri, H & Badve, S 2008, 'Amplified in breast cancer 1 expression in breast cancer', Histopathology, vol. 53, no. 6, pp. 634-641. https://doi.org/10.1111/j.1365-2559.2008.03155.x
Thorat MA, Turbin D, Morimiya A, Leung S, Zhang Q, Jeng MH et al. Amplified in breast cancer 1 expression in breast cancer. Histopathology. 2008 Dec;53(6):634-641. https://doi.org/10.1111/j.1365-2559.2008.03155.x
Thorat, M. A. ; Turbin, D. ; Morimiya, A. ; Leung, S. ; Zhang, Q. ; Jeng, M. H. ; Huntsman, D. G. ; Nakshatri, Harikrishna ; Badve, Sunil. / Amplified in breast cancer 1 expression in breast cancer. In: Histopathology. 2008 ; Vol. 53, No. 6. pp. 634-641.
@article{2603bf02d9ff4b18857dfd3af8aabc3a,
title = "Amplified in breast cancer 1 expression in breast cancer",
abstract = "Aims: The amplified in breast cancer 1 (AIB1), steroid receptor co-activator family member, acts as an oestrogen receptor (ER) co-activator. Acting with HER-2, it is thought to play a role in endocrine resistance by facilitating ER-growth factor crosstalk. The aim was to analyse AIB1 expression by immunohistochemistry and study its correlations with other prognostic variables in breast cancer and its effect on survival. Methods: A tissue microarray comprising tumours from 438 patients with 15.4 years' median follow-up was used. Interpretable AIB1 expression obtained in 395 patients was analysed along with other prognostic factors in breast cancer. Results: AIB1 expression scores ranged from 0 to 30; positive AIB1 expression (score > 14) was seen in 146/395 breast cancers; it correlated negatively with ER (P = 0.003) and progesterone receptor (PR) (P = 0.007), and positively with HER-2 (P = 0.005) and tumour grade (P = 0.014). It did not correlate with nodal status (P = 0.437). Among ER+ patients, AIB1 expression showed a trend towards loss of PR expression (29{\%} versus 20{\%}; P = 0.14). AIB1 did not predict survival on univariate or multivariate analysis. Conclusions: AIB1 expression correlates with HER-2 expression in breast cancer and shows a trend of association with loss of PR expression in ER+ tumours. Our study supports the postulated role of AIB1 in ER-growth factor interactions.",
keywords = "Amplified in breast cancer 1, Breast cancer, Human epidermal growth factor receptor 2, Oestrogen receptor, Prognosis, Steroid receptor co-activator 3",
author = "Thorat, {M. A.} and D. Turbin and A. Morimiya and S. Leung and Q. Zhang and Jeng, {M. H.} and Huntsman, {D. G.} and Harikrishna Nakshatri and Sunil Badve",
year = "2008",
month = "12",
doi = "10.1111/j.1365-2559.2008.03155.x",
language = "English",
volume = "53",
pages = "634--641",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Amplified in breast cancer 1 expression in breast cancer

AU - Thorat, M. A.

AU - Turbin, D.

AU - Morimiya, A.

AU - Leung, S.

AU - Zhang, Q.

AU - Jeng, M. H.

AU - Huntsman, D. G.

AU - Nakshatri, Harikrishna

AU - Badve, Sunil

PY - 2008/12

Y1 - 2008/12

N2 - Aims: The amplified in breast cancer 1 (AIB1), steroid receptor co-activator family member, acts as an oestrogen receptor (ER) co-activator. Acting with HER-2, it is thought to play a role in endocrine resistance by facilitating ER-growth factor crosstalk. The aim was to analyse AIB1 expression by immunohistochemistry and study its correlations with other prognostic variables in breast cancer and its effect on survival. Methods: A tissue microarray comprising tumours from 438 patients with 15.4 years' median follow-up was used. Interpretable AIB1 expression obtained in 395 patients was analysed along with other prognostic factors in breast cancer. Results: AIB1 expression scores ranged from 0 to 30; positive AIB1 expression (score > 14) was seen in 146/395 breast cancers; it correlated negatively with ER (P = 0.003) and progesterone receptor (PR) (P = 0.007), and positively with HER-2 (P = 0.005) and tumour grade (P = 0.014). It did not correlate with nodal status (P = 0.437). Among ER+ patients, AIB1 expression showed a trend towards loss of PR expression (29% versus 20%; P = 0.14). AIB1 did not predict survival on univariate or multivariate analysis. Conclusions: AIB1 expression correlates with HER-2 expression in breast cancer and shows a trend of association with loss of PR expression in ER+ tumours. Our study supports the postulated role of AIB1 in ER-growth factor interactions.

AB - Aims: The amplified in breast cancer 1 (AIB1), steroid receptor co-activator family member, acts as an oestrogen receptor (ER) co-activator. Acting with HER-2, it is thought to play a role in endocrine resistance by facilitating ER-growth factor crosstalk. The aim was to analyse AIB1 expression by immunohistochemistry and study its correlations with other prognostic variables in breast cancer and its effect on survival. Methods: A tissue microarray comprising tumours from 438 patients with 15.4 years' median follow-up was used. Interpretable AIB1 expression obtained in 395 patients was analysed along with other prognostic factors in breast cancer. Results: AIB1 expression scores ranged from 0 to 30; positive AIB1 expression (score > 14) was seen in 146/395 breast cancers; it correlated negatively with ER (P = 0.003) and progesterone receptor (PR) (P = 0.007), and positively with HER-2 (P = 0.005) and tumour grade (P = 0.014). It did not correlate with nodal status (P = 0.437). Among ER+ patients, AIB1 expression showed a trend towards loss of PR expression (29% versus 20%; P = 0.14). AIB1 did not predict survival on univariate or multivariate analysis. Conclusions: AIB1 expression correlates with HER-2 expression in breast cancer and shows a trend of association with loss of PR expression in ER+ tumours. Our study supports the postulated role of AIB1 in ER-growth factor interactions.

KW - Amplified in breast cancer 1

KW - Breast cancer

KW - Human epidermal growth factor receptor 2

KW - Oestrogen receptor

KW - Prognosis

KW - Steroid receptor co-activator 3

UR - http://www.scopus.com/inward/record.url?scp=57049128680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049128680&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2008.03155.x

DO - 10.1111/j.1365-2559.2008.03155.x

M3 - Article

VL - 53

SP - 634

EP - 641

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 6

ER -